The Latest Breaking News on Pharma

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Lantheus stock is approaching a new buy point on the stock market today after finding support at a key level in recent weeks.

Vaccine provides an alternative to flu shots administered with needles

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

While a ban on vape sales is starting to have an effect, Health Minister Mark Butler says further action is needed on stores that are illegally selling them.

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

The Gavi vaccine alliance has reached an agreement with Danish pharmaceutical company Bavarian Nordic to obtain 500,000 doses of mpox vaccine for African countries dealing with an outbreak of the virus.

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

The U.S. Drug Enforcement Administration is closing two of its offices in China, a move that comes even as the agency struggles to disrupt the flow of precursor chemicals from the country that have fueled a fentanyl epidemic